Iovance Biotherapeutics/$IOVA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Iovance Biotherapeutics
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Ticker
$IOVA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
838
Website
IOVA Metrics
BasicAdvanced
$1B
-
-$1.23
0.85
-
Price and volume
Market cap
$1B
Beta
0.85
52-week high
$12.50
52-week low
$1.64
Average daily volume
19M
Financial strength
Current ratio
4.178
Quick ratio
3.51
Long term debt to equity
5.759
Total debt to equity
6.996
Profitability
EBITDA (TTM)
-365.024
Gross margin (TTM)
21.72%
Net profit margin (TTM)
-176.49%
Operating margin (TTM)
-187.50%
Effective tax rate (TTM)
0.86%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
-27.14%
Return on equity (TTM)
-51.85%
Valuation
Price to revenue (TTM)
4.475
Price to book
1.36
Price to tangible book (TTM)
2.17
Price to free cash flow (TTM)
-2.739
Free cash flow yield (TTM)
-36.52%
Free cash flow per share (TTM)
-114.29%
Growth
Revenue change (TTM)
11,070.12%
Earnings per share change (TTM)
-31.83%
3-year earnings per share growth (CAGR)
-18.73%
10-year earnings per share growth (CAGR)
9.11%
What the Analysts think about IOVA
Analyst ratings (Buy, Hold, Sell) for Iovance Biotherapeutics stock.
Bulls say / Bears say
Iovance Biotherapeutics has expanded its manufacturing capacity at the Iovance Cell Therapy Center (iCTC) to treat over 5,000 patients annually, positioning the company to meet increasing demand for its TIL therapies. (BioSpace)
The company has secured a robust patent portfolio with over 250 granted or allowed U.S. and international patents, providing exclusivity for its therapies like Amtagvi through at least 2042, which could strengthen its competitive position. (BioSpace)
Iovance's recent leadership appointments, including a new Chief Commercial Officer and Chief Regulatory Officer, may enhance its strategic direction and regulatory navigation, potentially driving future growth. (BioSpace)
In Q1 2025, Iovance reported revenue of $49.3 million, significantly below analysts' expectations of $82.4 million, leading to a sharp stock price decline of approximately 44%. (Nasdaq)
The company reduced its full-year revenue guidance for 2025 to between $250 million and $300 million, down from the previous outlook of $450 million to $475 million, indicating potential challenges in meeting growth projections. (Nasdaq)
Iovance is facing a securities class action lawsuit alleging that it misled investors about its growth potential and operational readiness, which could lead to financial and reputational risks. (Texas Business Times)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
IOVA Financial Performance
Revenues and expenses
IOVA Earnings Performance
Company profitability
IOVA News
AllArticlesVideos
Here's why Iova stock surged 32% today and why the rally might not be over
Invezz·5 days ago
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
Business Wire·2 weeks ago
IOVA Deadline: Rosen Law Firm Urges Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Iovance Biotherapeutics stock?
Iovance Biotherapeutics (IOVA) has a market cap of $1B as of July 28, 2025.
What is the P/E ratio for Iovance Biotherapeutics stock?
The price to earnings (P/E) ratio for Iovance Biotherapeutics (IOVA) stock is 0 as of July 28, 2025.
Does Iovance Biotherapeutics stock pay dividends?
No, Iovance Biotherapeutics (IOVA) stock does not pay dividends to its shareholders as of July 28, 2025.
When is the next Iovance Biotherapeutics dividend payment date?
Iovance Biotherapeutics (IOVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Iovance Biotherapeutics?
Iovance Biotherapeutics (IOVA) has a beta rating of 0.85. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.